Country Trust Bank Sells 6,468 Shares of Eli Lilly and Company $LLY

Country Trust Bank cut its stake in Eli Lilly and Company (NYSE:LLY) by 6.8% in the 3rd quarter, Holdings Channel reports. The fund owned 89,222 shares of the company’s stock after selling 6,468 shares during the quarter. Eli Lilly and Company comprises about 1.5% of Country Trust Bank’s holdings, making the stock its 16th largest position. Country Trust Bank’s holdings in Eli Lilly and Company were worth $68,076,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in LLY. Occidental Asset Management LLC increased its position in shares of Eli Lilly and Company by 0.7% during the 2nd quarter. Occidental Asset Management LLC now owns 1,966 shares of the company’s stock valued at $1,533,000 after purchasing an additional 13 shares during the last quarter. New Insight Wealth Advisors boosted its stake in Eli Lilly and Company by 3.4% in the second quarter. New Insight Wealth Advisors now owns 394 shares of the company’s stock worth $307,000 after buying an additional 13 shares in the last quarter. Dash Acquisitions Inc. boosted its stake in Eli Lilly and Company by 2.8% in the second quarter. Dash Acquisitions Inc. now owns 485 shares of the company’s stock worth $387,000 after buying an additional 13 shares in the last quarter. Nvest Financial LLC grew its position in Eli Lilly and Company by 0.6% during the second quarter. Nvest Financial LLC now owns 2,274 shares of the company’s stock valued at $1,773,000 after acquiring an additional 13 shares during the last quarter. Finally, MPS Loria Financial Planners LLC raised its stake in shares of Eli Lilly and Company by 1.9% during the second quarter. MPS Loria Financial Planners LLC now owns 699 shares of the company’s stock worth $545,000 after acquiring an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Down 3.8%

NYSE LLY opened at $1,032.51 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The stock has a market capitalization of $976.11 billion, a PE ratio of 50.51, a PEG ratio of 0.78 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The business’s 50-day moving average is $1,049.04 and its 200 day moving average is $868.38.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same period last year, the company earned $1.18 EPS. The business’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s payout ratio is presently 29.35%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Nvidia announced a major AI drug‑discovery collaboration with a reported $1 billion lab investment, reinforcing long‑term R&D acceleration and partnership value for Lilly. Nvidia And Eli Lilly To Build $1 Billion AI-Powered Drug Discovery Lab
• Positive Sentiment: Jefferies reaffirmed a Buy and set a $1,300 price target; other street notes (BMO, TipRanks coverage) continue to emphasize Lilly’s leadership in incretin/GLP‑1 franchises and multitherapy growth. This supports medium‑term upside expectations. Where is Eli Lilly and Company (LLY) Headed According to Analysts?
• Positive Sentiment: J.P. Morgan notes obesity remains front‑and‑center and reported Q4 sales beats, highlighting Lp(a) cardiovascular drugs as an additional growth lever beyond weight‑loss therapies. These messages bolster earnings durability. JPM26 Day 1: Obesity Front-and-Center, Q4 Sales Beats
• Positive Sentiment: Analysts and sell‑side notes (Zacks) point to continued strong demand for Mounjaro and Zepbound, with improving supply and global uptake offsetting pricing pressure — a near‑term revenue tailwind. How Will Mounjaro and Zepbound Sales Aid LLY’s Upcoming Q4 Results?
• Neutral Sentiment: Mixed media/opinion pieces debate valuation after a strong 2025 gain; some argue to trim exposure while many funds still list Lilly as a long‑term growth holding — suggests investor positioning remains contested. Eli Lilly: Sell It And Buy Novo Nordisk Instead
• Negative Sentiment: A compounding pharmacy sued Lilly and Novo Nordisk in Texas alleging coordinated conduct to limit access to GLP‑1s, raising legal and reputational risk that could pressure pricing/access; markets treat litigation risk as a near‑term negative. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy
• Negative Sentiment: The FDA reportedly delayed a decision on Lilly’s oral obesity pill orforglipron (and other priority voucher awardees), a regulatory setback that catalyzed intraday selling as it defers potential market expansion vs. peers. FDA Delays Decision for Lilly’s Obesity Pill Orforglipron, Other Priority Voucher Awardees: Report

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Bank of America cut their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Cantor Fitzgerald reissued an “overweight” rating on shares of Eli Lilly and Company in a research note on Monday, December 1st. Loop Capital set a $950.00 price objective on Eli Lilly and Company in a research note on Monday, November 10th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Five equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $1,174.70.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.